Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanjay Popat

Showing results (211-220 of 273) with videos related to

Pageof 28
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2026
Reply to: "Beyond Response Rates: Interpreting Long-Term Benefit in CheckMate 743" and "Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743"Arnaud Scherpereel, Aaron S Mansfield, Francesco Grossi, et al.
European Journal of Cancer (Oxford, England : 1990)|February 7, 2020
CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populationsEnriqueta Felip, Andrea Ardizzoni, Tudor Ciuleanu, et al.
Lancet (London, England)|January 24, 2021
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trialPaul Baas, Arnaud Scherpereel, Anna K Nowak, et al.
Lung Cancer (Amsterdam, Netherlands)|January 7, 2025
FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)Alexander Spira, Byoung Chul Cho, Enriqueta Felip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2026
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743Arnaud Scherpereel, Paul Baas, Anna K Nowak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2026
Erratum: Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743Arnaud Scherpereel, Paul Baas, Anna K Nowak, et al.
The Oncologist|April 17, 2026
Characterization and Clinical Management of Adverse Events Following Treatment with Repotrectinib: A TRIDENT-1 AnalysisAlexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
The Oncologist|May 8, 2026
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysisAlexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
The Lancet Regional Health. Europe|March 13, 2024
Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancerVincent D de Jager, Wim Timens, Arnaud Bayle, et al.
Journal for Immunotherapy of Cancer|October 25, 2023
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesotheliomaKrisztian Homicsko, Panagiota Zygoura, Maxim Norkin, et al.
Pageof 28

Showing results (211-220 of 273) with videos related to

Sort By:
Pageof 28
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2026
Reply to: "Beyond Response Rates: Interpreting Long-Term Benefit in CheckMate 743" and "Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743"Arnaud Scherpereel, Aaron S Mansfield, Francesco Grossi, et al.
European Journal of Cancer (Oxford, England : 1990)|February 7, 2020
CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populationsEnriqueta Felip, Andrea Ardizzoni, Tudor Ciuleanu, et al.
Lancet (London, England)|January 24, 2021
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trialPaul Baas, Arnaud Scherpereel, Anna K Nowak, et al.
Lung Cancer (Amsterdam, Netherlands)|January 7, 2025
FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)Alexander Spira, Byoung Chul Cho, Enriqueta Felip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2026
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743Arnaud Scherpereel, Paul Baas, Anna K Nowak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2026
Erratum: Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743Arnaud Scherpereel, Paul Baas, Anna K Nowak, et al.
The Oncologist|April 17, 2026
Characterization and Clinical Management of Adverse Events Following Treatment with Repotrectinib: A TRIDENT-1 AnalysisAlexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
The Oncologist|May 8, 2026
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysisAlexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
The Lancet Regional Health. Europe|March 13, 2024
Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancerVincent D de Jager, Wim Timens, Arnaud Bayle, et al.
Journal for Immunotherapy of Cancer|October 25, 2023
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesotheliomaKrisztian Homicsko, Panagiota Zygoura, Maxim Norkin, et al.
Pageof 28